Enterprise Europe Network

Slovak scientific and research institute in cooperation with a Slovak university have developed a new honey preparation for the local treatment of long-term non-healing wounds and are looking for a licensee

Country of origin:
Country: 
SLOVAKIA
Opportunity:
External Id: 
TOSK20200807001
Published
12/08/2020
Last update
10/09/2021
Expiration date
11/09/2022

Keywords

Partner keyword: 
Virus, Virology/Antibiotics/Bacteriology
Ophthalmology, ear, nose and throat diseases
Other medical/health related (not elsewhere classified)
EXPRESS YOUR INTEREST

Summary

Summary: 
An innovative honey preparation for the local treatment of long-term non-healing wounds has been developed by a team of inventors from an established Slovak scientific and research institute and a Slovak university. The novelty of the honey preparation consists in the use of a combination of ascorbic acid with honey to increase the antibacterial and antibiofilm potential of honey against pathogens of chronic wounds. The preferred cooperation type is license agreement.

Description

Description: 

Nowadays, the term “medical honey” is becoming increasingly known to the professional and also general public. Products or medical aids, which are based on such honey, are emerging on the world market. It is certified honey that can be used for therapeutic purposes, especially for the treatment of burn injuries and acute and chronic wounds.
In addition to quality parameters, medicinal honeys have significant biological properties. Emphasis is placed especially on their antibacterial properties. Honey as a natural product is a source of trace elements, vitamins, amino acids and so on. A natural component of honey is also ascorbic acid (vitamin C). Although honey has certain antibiofilm properties, its effect is limited and dilution of honey may on the contrary induce stimulation of biofilm formation in the wound. For this reason, it is necessary to enrich honey with naturally occurring substances in honey, which have a biological effect without negative side effects, and to increase its effect against planktonic as well as biofilm-bound bacteria, in particular Gram-negative bacteria.
Honey intended for direct clinical application must be sterilized, most often by means of ionizing radiation, which does not have a negative effect on the antibacterial or antibiofilm activity of honey. However, ionizing radiation can cause destruction or subsequent aggregation of proteins/peptides in honey. Destruction of proteins/peptides in honey can be prevented by the addition of specific protective substances, thus preserving its antibacterial capacity.
A team of inventors from a Slovak scientific and research institute and a Slovak university has managed to substantially eliminate the above-mentioned shortcomings by adding (in appropriate amounts) ascorbic acid to honey, which is usually used as an antioxidant or a means of lowering the pH. The addition of ascorbic acid to honey intended for medical use has increased its antibacterial and antibiofilm activity. In addition, ascorbic acid stabilizes biologically active substances of the peptides/proteins type against undesired degradation or aggregation during the sterilization process by ionizing radiation.
The use of the preparation is expected primarily in wound healing management and ophthalmology, but also wherever it is necessary to locally eliminate bacterial infection.

The proprietors of the technology are looking for an industrial partner for licensing the technology. More details described in the Partner Sought.

Advantages & innovations

Cooperation plus value: 
Competitive advantage: • increase of antibacterial and antibiofilm activity of honeys (2- to 5-fold against Gram-negative bacteria), which are planned or are already being used in clinical practice, while it may be honeys of different botanical and geographical origin, • stabilization of antibacterial components of honey (bee antibacterial/antibiofilm peptide) even during the process of honey sterilization by means of ionizing radiation.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The use of the preparation is expected primarily in wound healing management and ophthalmology, but also wherever it is necessary to locally eliminate bacterial infection. Type of partner: The proprietors of the technology are looking for an industrial partner for licensing the technology. Role: License agreement - the Slovak research institute is looking for licensees. The Slovak scientific and research institute would like to increase third part funding of the research Institute.

Type and size

Cooperation task: 
SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500